Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Stay Ahead of the Game With Biogen Inc. (BIIB) Q4 Earnings: Wall Street's Insights on Key Metrics
10:21am, Thursday, 08'th Feb 2024
Evaluate the expected performance of Biogen Inc. (BIIB) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key met
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Tuesday, 06'th Feb 2024
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Inc. (BIIB) Stock Drops Despite Market Gains: Important Facts to Note
06:51pm, Friday, 02'nd Feb 2024
In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $243.72, denoting a -1.66% change from the preceding trading day.
Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm
11:31am, Thursday, 01'st Feb 2024
Biogen (BIIB) aims to build a leading Alzheimer's disease franchise with the new drug Leqembi. The company quits commercializing the controversial Alzheimer's disease drug, Aduhelm.
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
11:43am, Wednesday, 31'st Jan 2024
Biogen said its decision to drop Aduhelm, which had a polarizing approval and launch, was "not related to any safety or efficacy concerns."
Biogen Ends Development of Alzheimer's Drug Aduhelm
08:55am, Wednesday, 31'st Jan 2024
The biotechnology company says it will record a one-time charge of about $60 million related to close-out costs.
Biogen halts development of controversial Alzheimer's drug
07:54am, Wednesday, 31'st Jan 2024
Biogen Inc. BIIB, -0.18% said Wednesday that it will halt the development and commercialization of its Alzheimer's drug Aduhelm, which drew intense scrutiny of its U.S. regulatory approval process due
Biogen Inc. (BIIB) Laps the Stock Market: Here's Why
06:56pm, Monday, 29'th Jan 2024
Biogen Inc. (BIIB) closed at $247.52 in the latest trading session, marking a +1.1% move from the prior day.
Will Biogen Inc. (BIIB) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Monday, 29'th Jan 2024
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biogen Inc. (BIIB) Rises Higher Than Market: Key Facts
06:56pm, Tuesday, 23'rd Jan 2024
Biogen Inc. (BIIB) closed the most recent trading day at $251.68, moving +1.36% from the previous trading session.
These Could Be the Biggest Nasdaq-100 Winners in 2024, According to Wall Street
05:50am, Thursday, 18'th Jan 2024
Two of Wall Street's favorite Nasdaq-100 stocks for 2024 are communications and media giants. The third stock that analysts think will soar this year is a biotech with a promising new drug on the mark
Time to Load Up on This New Magnificent 7 of ‘Strong Buy' Stocks
12:26pm, Friday, 12'th Jan 2024
Wall Street analysts tend to always look on the bright side of life. (Cue the Monty Python song).
Biogen Inc. (BIIB) Registers a Bigger Fall Than the Market: Important Facts to Note
07:37pm, Tuesday, 09'th Jan 2024
In the latest trading session, Biogen Inc. (BIIB) closed at $255.84, marking a -0.83% move from the previous day.
China approves Alzheimer's treatment Leqembi by Eisai and Biogen
05:19am, Tuesday, 09'th Jan 2024
Eisai and Biogen said on Tuesday that their Alzheimer's treatment Leqembi had won approval in China, the third country after the United States and Japan.
2 low-priced gene therapy stocks to speculate on
08:26am, Monday, 08'th Jan 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic differences.
